Liminal BioSciences Inc.
LMNL · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -17.6% | -43.6% | 7,933.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,907.1% | -5,231.6% | -5,686.3% | -335,966.7% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -8,161.6% | -5,623.5% | -1,980.1% | 730,500% |
| EPS Diluted | -2.94 | -2.46 | -1.54 | 7 |
| % Growth | -19.5% | -59.7% | -122% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |